Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.

Abstract:

:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior in the tumor microenvironment; it mediates cell-cell adhesion, binding of myeloma cells to type I collagen, and inhibits tumor cell invasion into collagen gels. In addition, syndecan-1 is released from the surface of myeloma cells and this shed form of the molecule inhibits growth and induces apoptosis of myeloma cells and may modulate myeloma bone disease by inhibiting osteoclast formation and promoting osteoblast formation. In view of its effects on tumor cell growth, survival, adhesion and invasion and on bone cell differentiation, syndecan-1 may be an important potentially beneficial regulator of myeloma pathobiology. Further studies are needed to define the clinical significance of syndecan-1 in myeloma and to examine its functional significance in other lymphoid malignancies.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Dhodapkar MV,Sanderson RD

doi

10.3109/10428199909083378

keywords:

subject

Has Abstract

pub_date

1999-06-01 00:00:00

pages

35-43

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

34

pub_type

杂志文章,评审
  • Acute myeloid leukemia with inv(8)(p11q13).

    abstract::A patient with acute monoblastic leukemia (AML M5a) and the pericentric inversion inv(8)(p11q13) as well as additional chromosome abnormalities in her bone marrow cells is described. This is the fourth known case of inv(8)(p11q13)-positive acute leukemia, and the second such case in which gain of 1q material occurred ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009113397

    authors: Panagopoulos I,Teixeira MR,Micci F,Hammerstrøm J,Isaksson M,Johansson B,Mitelman F,Heim S

    更新日期:2000-11-01 00:00:00

  • Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

    abstract::The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1613540

    authors: Stahl M,Tallman MS

    更新日期:2019-12-01 00:00:00

  • Chronic lymphocytic leukemia complicated by plasmacytoma originating from different clones.

    abstract::In a woman with chronic lymphocytic leukemia (CLL), a plasmacytoma developed on the back region after four years. CLL cases complicated with plasmacytoma are rare. In the present case, the plasmacytoma showed kappa cytoplasmic immunoglobulin (Ig), and the CLL showed gamma lambda surface Ig. To reveal the clonal origin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053555

    authors: Yahata N,Iwase O,Iwama H,Tauchi T,Kawanishi Y,Serizawa H,Ohyashiki K

    更新日期:2000-09-01 00:00:00

  • The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.

    abstract::We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039008

    authors: Schultz KR,Gilman AL

    更新日期:1997-01-01 00:00:00

  • High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.

    abstract::The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1233540

    authors: Muchtar E,Magen H,Gertz MA

    更新日期:2017-06-01 00:00:00

  • Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

    abstract::Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1231405

    authors: Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Rojas L,Martínez-Cuadrón D,Hervás D,Boluda B,García-Robles A,Rodríguez-Veiga R,Martín-Cerezuela M,Cervera J,Sendra L,Sanz J,Miguel A,Lorenzo I,Poveda JL,Sanz

    更新日期:2017-05-01 00:00:00

  • Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.

    abstract::Matrix high-throughput screening (HTS) methods are increasingly employed to rapidly define potential therapeutic drug combinations. We used combination HTS to identify compounds showing synergistic anti-proliferative activity with ibrutinib, an irreversible, small-molecule inhibitor of Bruton's tyrosine kinase. The go...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1349899

    authors: Schaffer M,Chaturvedi S,Davis C,Aquino R,Stepanchick E,Versele M,Liu Y,Yang J,Lu R,Balasubramanian S

    更新日期:2018-04-01 00:00:00

  • Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

    abstract::Recent data suggest that myeloid neoplasms are organized hierarchically in terms of self-renewal and maturation of early progenitor cells, similar to normal myelopoiesis. In acute myeloid leukemia (AML), the NOD/SCID mouse-repopulating leukemic stem cells usually co-express CD123 with CD34, but lack CD38. So far, howe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500272507

    authors: Florian S,Sonneck K,Hauswirth AW,Krauth MT,Schernthaner GH,Sperr WR,Valent P

    更新日期:2006-02-01 00:00:00

  • Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

    abstract::Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indir...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802005191

    authors: Vallet S,Palumbo A,Raje N,Boccadoro M,Anderson KC

    更新日期:2008-07-01 00:00:00

  • Endogenous tumor necrosis factor and doxorubicin sensitivity in leukemic patients.

    abstract::Sensitivity to doxorubicin (DOX) and expression of intracellular endogenous TNF (enTNF) or manganous superoxide dismutase (MnSOD) activity were found to be inversely correlated in leukemic cells from 19 patients (6 acute lymphoblastic leukemia, 13 acute myeloblastic leukemia). In a case with acquired resistance to che...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057560

    authors: Watanabe N

    更新日期:1998-08-01 00:00:00

  • The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor †.

    abstract::In Hodgkin lymphoma (HL) bleomycin can induce pulmonary toxicity (BPT). BPT consists of respiratory tract symptoms during bleomycin-exposure and radiologic pulmonary lesions without concomitant infection. Older age, bleomycin dose, smoking history and the use of granulocyte-colony stimulating factor (G-CSF) have been ...

    journal_title:Leukemia & lymphoma

    pub_type: 历史文章,杂志文章

    doi:10.1080/10428194.2018.1515939

    authors: Andersen MD,Kamper P,d'Amore A,Clausen M,Bentzen H,d'Amore F

    更新日期:2019-04-01 00:00:00

  • Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

    abstract::The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1214953

    authors: Manasanch EE,de Larrea CF,Zingone A,Steinberg SM,Kwok M,Tageja N,Bhutani M,Kazandjian D,Roschewski M,Wu P,Carter G,Zuchlinski D,Mulquin M,Lamping L,Costello R,Burton D,Gil LA,Figg WD,Maric I,Calvo KR,Yuan C,Stet

    更新日期:2017-03-01 00:00:00

  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.

    abstract::Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600774923

    authors: Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

    更新日期:2006-10-01 00:00:00

  • What is the best treatment for acute promyelocytic leukemia?

    abstract::The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309064259

    authors: Avvisati G,Petti MC,Mandelli F

    更新日期:1993-01-01 00:00:00

  • The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.

    abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600757894

    authors: Micallef IN,Remstein ED,Ansell SM,Colgan JP,Inwards DJ,Johnston PB,Lewis JT,Markovic SN,Porrata LF,White WL,Witzig TE,Ristow K,Habermann TM

    更新日期:2006-09-01 00:00:00

  • Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.

    abstract::A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.3109/10428194.2011.605918

    authors: Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

    更新日期:2012-02-01 00:00:00

  • R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.

    abstract::Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. In this retrospective study, we evaluated changes in vertebral bone density (VD) in DLBCL patients by measuring CT-ascertained Hounsfield units (HU) at the L3 level. In total, 111 patients dia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1233543

    authors: Svendsen P,Shekhrajka N,Nielsen KL,Vestergaard P,Poulsen MØ,Vistisen AK,Munksgaard PS,Severinsen MT,Jensen P,Johnsen HE,Jakobsen LH,Bøgsted M,Frøkjær JB,El-Galaly TC

    更新日期:2017-05-01 00:00:00

  • Cytokine receptor gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation.

    abstract::Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509107899

    authors: Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

    更新日期:1995-10-01 00:00:00

  • Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

    abstract::The pattern of disease relapse in nine patients with multiple myeloma who had received double hemi body irradiation therapy is analysed. This analysis highlights the localisation of these relapses to skeletal areas excluded from initial radiation fields. This phenomenon was also documented in a patient who received sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042484

    authors: Giles FJ,Lord CD,Gaminarai EJ,Grants IR,Kearney JW,Mills MJ,Newland AC,Nikoskelainen J,Pelliniemi T,Richards JD,Rostom AC,Tobias JS,Trask CT,Goldstone AH

    更新日期:1990-01-01 00:00:00

  • Treatment of young relapsed Hodgkin's disease patients with high-dose chemotherapy followed by peripheral blood stem cell transplantation.

    abstract::Four patients less than 20 years of age with Hodgkin's disease, who had developed either second or third relapse, were treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT). Peripheral blood stem cells (PBSC) were collected after the administration of high-dose cytosine ara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509059652

    authors: Matsuzaki A,Okamura J,Nagatoshi Y,Kai T,Ohga S,Gondo H,Inaba S,Ueda K

    更新日期:1995-08-01 00:00:00

  • Expression of sialosyl-T and disialosyl-T antigens in erythroid cells.

    abstract::Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039027

    authors: Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

    更新日期:1997-05-01 00:00:00

  • Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

    abstract::Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400003267

    authors: Arora B,Mesa R,Tefferi A

    更新日期:2004-12-01 00:00:00

  • Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability.

    abstract::The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003 and June 2006, in w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2012.698739

    authors: Intragumtornchai T,Bunworasate U,Siritanaratkul N,Khuhapinant A,Nawarawong W,Norasetthada L,Lekhakula A,Rujirojindakul P,Sirijerachai C,Chansung K,Suwanban T,Chuncharunee S,Niparuck P,Wongkhantee S,Mongkonsritragoon W,Numbe

    更新日期:2013-01-01 00:00:00

  • Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006411

    authors: Wang P,Pavletic ZS,Joshi SS

    更新日期:2002-09-01 00:00:00

  • Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.738365

    authors: Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

    更新日期:2013-05-01 00:00:00

  • Primary breast lymphoma.

    abstract::Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma. Few reports are available in the literature concerning its treatment and outcome. Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had ad...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000079195

    authors: Gholam D,Bibeau F,El Weshi A,Bosq J,Ribrag V

    更新日期:2003-07-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

    abstract::Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) an...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819031000077025

    authors: Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

    更新日期:2003-06-01 00:00:00

  • A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

    abstract::Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2010.546015

    authors: Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

    更新日期:2011-03-01 00:00:00

  • Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia.

    abstract::The age-adjusted incidence of Hodgkin's lymphoma (HL) is markedly higher in Saudi Arabia than in the USA, and accounts for 10.5% of all neoplasias in children aged 15 years or older in Saudi Arabia. Epstein-Barr virus (EBV) infection has been suspected to cause high HL incidence in developing countries. To investigate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500286879

    authors: Al-Kuraya K,Narayanappa R,Al-Dayel F,El-Solh H,Ezzat A,Ismail H,Belgaumi A,Bavi P,Atizado V,Sauter G,Simon R

    更新日期:2006-04-01 00:00:00

  • DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin.

    abstract::DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1533128

    authors: Wang J,Van Den Berg D,Hwang AE,Weisenberger D,Triche T,Nathwani BN,Conti DV,Siegmund K,Mack TM,Horvath S,Cozen W

    更新日期:2019-06-01 00:00:00